<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01276379</url>
  </required_header>
  <id_info>
    <org_study_id>GEMCAD-1002</org_study_id>
    <secondary_id>2010-019236-12</secondary_id>
    <nct_id>NCT01276379</nct_id>
  </id_info>
  <brief_title>Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab</brief_title>
  <acronym>POSIBA</acronym>
  <official_title>Single-Arm, Multicenter, Prospective, Phase 2 Study for the Evaluation of Biomarkers in Patients With Advanced &amp;/or Metastatic Colorectal Cancer With Wild Type KRAS Treated Biweekly With Chemotherapy and Cetuximab as First-Line Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol Multidisciplinario del Cancer Digestivo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Espanol Multidisciplinario del Cancer Digestivo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Advanced colorectal cancer (ACRC) is a heterogeneous disease and classification of patients&#xD;
      is nowadays inefficient. Roughly twenty per cent of patients present with favorable figures&#xD;
      (less than 4 liver nodules and less than 5 cm) and are suitable for local treatments (surgery&#xD;
      or local-ablative therapies). Additionally, 10-15% of patients have poor performance status&#xD;
      (PS &gt;2) or are severe disabled due to geriatric syndromes or/and co-morbid diseases that&#xD;
      preclude any treatment strategies than best supportive care alone. The rest of patients (fit&#xD;
      patients not suitable for radical treatments) constitute the population of patients treated&#xD;
      with palliative therapies. Despite of it not all these patients have the same prognosis.&#xD;
      Patients with PS 0,1 and levels of LDH &lt;ULN (Intermediate-risk patients) have better PFS and&#xD;
      OS irrespective of therapy in all randomized clinical trials (de Gramont et al, JCO 2000;&#xD;
      Douillard et al, Lancet 2000; Koopman et al, 2007).&#xD;
&#xD;
      CRYSTAL trial shows a benefit in PFS (1.5 months) in RASWT of FOLFIRI plus cetuximab compared&#xD;
      with FOLFIRI alone. Nowadays the selection of patients for cetuximab treatment is based on&#xD;
      mutational status of KRAS, which allow to select those patients who will not respond to&#xD;
      therapy. Other surrogate markers of activity should be also evaluated. Our hypothesis is that&#xD;
      the suggested biomarkers will allow the selection of the patients who will benefit the most&#xD;
      from the biweekly cetuximab treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">December 21, 2017</completion_date>
  <primary_completion_date type="Actual">March 15, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>4 years</time_frame>
    <description>Measurements according to RECIST 1.1 criteria (Response Evaluation Criteria in Solid Tumors). Main techniques: CT-scan. Two groups will be defined based on the score built from the proposed clinical variables and biomarkers. Instead of a binomial distribution, a Log-rank method has been used to calculate the sample size in order to include all the incidents during the follow-up. Expecting a minimum 20% difference (60 vs. 40%) on PFS at 12 months between groups and with the following assumptions:&#xD;
Alpha error (bilateral): 5% Beta error: 20% Results are reported by subgroups to compare outcome measure according to BRAF mutation. All patients belong to same treatment/study arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>4 years</time_frame>
    <description>Measured as time in months from start of study treatment to death or lost to follow up.&#xD;
Results are reported by subgroups to compare outcome measure according to BRAF mutation. All patients belong to same treatment/study arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Duration</measure>
    <time_frame>4 years</time_frame>
    <description>Duration of the partial or total response to the treatment. Evaluation and classification according to RECIST 1.1 criteria (Response Evaluation Criteria in Solid Tumors)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>4 years</time_frame>
    <description>Frequency and type of adverse events (AEs). AEs were coded according to NCI CTCAE V3.0 and classified by frequency, relatedness to study treatment (related/not related) and severity (Grade).&#xD;
Severity ranges from grade 1 (low intensity) to Grade 5 (max. intensity, death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Biomarkers Analysis</measure>
    <time_frame>4 years</time_frame>
    <description>The secondary biomarkers in serum and tumoral tissue will be analysed in order to predict the acquired resistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumoral Response</measure>
    <time_frame>4 years</time_frame>
    <description>Measurements according to RECIST 1.1 criteria (Response Evaluation Criteria in Solid Tumors). Main techniques: CT-scan. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR Results are reported by subgroups to compare outcome measure according to BRAF mutation. All patients belong to same treatment/study arm.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">221</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFIRI (m) or FOLFOX-6 (m) + cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOX/FOLFIRI + cetuximab 500mg/m2 bi-weekly for 6 months, then bi-weekly cetuximab as monotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI (m)</intervention_name>
    <description>FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.</description>
    <arm_group_label>FOLFIRI (m) or FOLFOX-6 (m) + cetuximab</arm_group_label>
    <other_name>folinic acid, fluorouracil and irinotecan.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX-6 (m)</intervention_name>
    <description>FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.</description>
    <arm_group_label>FOLFIRI (m) or FOLFOX-6 (m) + cetuximab</arm_group_label>
    <other_name>folinic acid, fluorouracil and oxaliplatin.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>- 500 mg/m2 i.v. Every 2 weeks.</description>
    <arm_group_label>FOLFIRI (m) or FOLFOX-6 (m) + cetuximab</arm_group_label>
    <other_name>erbitux</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, age ≥ 18 years&#xD;
&#xD;
          -  Able to sign an informed consent form&#xD;
&#xD;
          -  Advanced and/or metastatic colorectal cancer&#xD;
&#xD;
          -  Colorectal cancer with KRAS wild type genotype&#xD;
&#xD;
          -  At least one unidimensionally measurable lesion according to RECIST criteria (1.1&#xD;
             revised) (to be assessed ≤ 28 days prior to the study treatment)&#xD;
&#xD;
          -  All patients with the following features will be included:&#xD;
&#xD;
               1. Progression free survival &gt; 6 months after adjuvant treatment +/- radiotherapy&#xD;
&#xD;
               2. &quot;De novo&quot; diagnosis of the disease&#xD;
&#xD;
          -  Performance ECOG status of 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Adequate bone marrow function: neutrophils ≥1,5 x 10^9/L; platelets ≥ 100 x 10^9/L;&#xD;
             hemoglobin ≥9 g/dL.&#xD;
&#xD;
          -  Adequate liver, renal and hematological function as follows:&#xD;
&#xD;
               1. Adequate liver function: SGOT and SGPT 2.5 x ULN (5 x ULN in case of hepatic&#xD;
                  metastasis). Total bilirubin &lt; 1,5 x ULN. Alkaline phosphatase 2,5 x LSN (5 x ULN&#xD;
                  if hepatic metastasis or 10 x ULN if bone metastasis)&#xD;
&#xD;
               2. Creatinine clearance or creatinine clearance during 24 hours ≥ 50 mL/min&#xD;
&#xD;
               3. Magnesium ≥ LLN, calcium ≥ LLN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PS &gt; 2 or elderly patients with fragility criteria&#xD;
&#xD;
          -  Previous surgery for metastasis&#xD;
&#xD;
          -  Previous systemic treatment for the metastatic colorectal cancer&#xD;
&#xD;
          -  Previous treatment with antibodies anti-EGFR or treatment with small-molecule EGFR&#xD;
             tyrosine kinase inhibitors or EGFR signal transduction inhibitors. Subjects who&#xD;
             suspend their first dose due to a reaction to the infusion can participate&#xD;
&#xD;
          -  Central nervous system metastasis (except: treated subjects with asymptomatic CNS&#xD;
             metastasis who have not received steroids within the 30 days prior to inclusion)&#xD;
&#xD;
          -  Prior malignant tumor in the last 5 years, except: basal cell carcinoma of the skin or&#xD;
             pre-invasive cervical cancer&#xD;
&#xD;
          -  Unresolved toxicities from a prior systemic treatment which do not qualify the patient&#xD;
             for inclusion&#xD;
&#xD;
          -  Presence of peripheral neuropathy (degree &gt; 1 in the ctc version 3.0) and serious&#xD;
             nonhealing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Hormonal treatment, immunotherapy or experimental or approved antibodies/proteins ≤ 30&#xD;
             days before the inclusion&#xD;
&#xD;
          -  Uncontrolled serious cardiovascular disease or: congestive cardiac failure NYHA lll or&#xD;
             lV, unstable angina pectoris, myocardial infarction precedents in the past 12 months,&#xD;
             significant arrhythmias&#xD;
&#xD;
          -  Interstitial pneumonitis or pulmonary fibrosis precedents, or interstitial pneumonitis&#xD;
             or pulmonary fibrosis signs on the thoracic CT-scan&#xD;
&#xD;
          -  Treatment for systemic infection within the 14 days prior to treatment&#xD;
&#xD;
          -  Acute/subacute intestinal occlusion and/or active inflammatory bowel disease or any&#xD;
             other bowel disease producing chronic diarrhea&#xD;
&#xD;
          -  Precedent of Gilbert's syndrome or dihydropyrimidine dehydrogenase deficiency&#xD;
&#xD;
          -  Precedent of any disease which can increase the risks associated to the participation&#xD;
             in the study or interfere in the study results&#xD;
&#xD;
          -  Known positive test for the following infections: HIV, Hepatitis C + abnormal liver&#xD;
             enzymes values, active chronic Hepatitis B (except Hepatitis C seropositive with&#xD;
             normal liver enzymes)&#xD;
&#xD;
          -  All concurrent diseases which can increase the toxicity risk&#xD;
&#xD;
          -  The individual presents a disorder of any kind which jeopardizes their ability to give&#xD;
             their written consent form and/or fulfill the study procedures&#xD;
&#xD;
          -  Any investigational agent within 30 days before enrolment&#xD;
&#xD;
          -  Pregnant or breastfeeding woman, or planning to get pregnant within the 6 months after&#xD;
             treatment&#xD;
&#xD;
          -  Surgery (excluding the diagnostic biopsy or placing of a central venous catheter)&#xD;
&#xD;
          -  Woman or man of childbearing potential not consenting to use adequate contraceptive&#xD;
             precautions during the study and 6 months after de last administration for women, and&#xD;
             1 month for men&#xD;
&#xD;
          -  Unability to fulfill the study requirements by the patients&#xD;
&#xD;
          -  Psychological, family, sociological or geographical conditions that may interfere with&#xD;
             the fulfillment of the study protocol and the follow-up calendar&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesús García Foncillas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Grupo Espanol Multidisciplinario del Cancer Digestivo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier García-Albeniz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Grupo Espanol Multidisciplinario del Cancer Digestivo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Provincial de Castellón</name>
      <address>
        <city>Castelló de la Plana</city>
        <state>Castellón</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma</city>
        <state>Malllorca</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llàtzer</name>
      <address>
        <city>Palma</city>
        <state>Mallorca</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Albacete</name>
      <address>
        <city>Albacete</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Cristina de Badajoz</name>
      <address>
        <city>Badajoz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Barbastro</name>
      <address>
        <city>Barbastro</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Yagüe</name>
      <address>
        <city>Burgos</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Jaume de Calella</name>
      <address>
        <city>Calella</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Jaén</name>
      <address>
        <city>Jaén</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Gran Canaria Dr. Negrín</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Jimenez Díaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Móstoles</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Mataró</name>
      <address>
        <city>Mataró</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sagunto</name>
      <address>
        <city>Sagunto</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <link>
    <url>http://www.gemcad.es/</url>
    <description>GEMCAD group</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 12, 2011</study_first_submitted>
  <study_first_submitted_qc>January 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2011</study_first_posted>
  <results_first_submitted>May 17, 2021</results_first_submitted>
  <results_first_submitted_qc>June 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2021</results_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>advanced</keyword>
  <keyword>metastatic</keyword>
  <keyword>KRAS</keyword>
  <keyword>biomarkers (BRAF, IGF1P/MMp7,PI3K-PTEN)</keyword>
  <keyword>cetuximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 23, 2010</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT01276379/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 27, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT01276379/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All patients were allocated in the same treatment arm. Some patient characteristics and results may be reported according to the mutational status of the patients despite all patients received the same treatment schedule</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab</title>
          <description>FOLFOX/FOLFIRI + cetuximab 500mg/m2 bi-weekly for 6 months, then bi-weekly cetuximab as monotherapy.&#xD;
FOLFIRI (m): FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
FOLFOX-6 (m): FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
Cetuximab: - 500 mg/m2 i.v. Every 2 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="221"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screening failure</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Evaluable patients</population>
      <group_list>
        <group group_id="B1">
          <title>WT BRAF - FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab</title>
          <description>Patients with a determination of BRAF status and presence of Wild type (WT) BRAF gen.&#xD;
FOLFOX/FOLFIRI + cetuximab 500mg/m2 bi-weekly for 6 months, then bi-weekly cetuximab as monotherapy.&#xD;
FOLFIRI (m): FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
FOLFOX-6 (m): FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
Cetuximab: - 500 mg/m2 i.v. Every 2 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Mutant BRAF - FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab</title>
          <description>Patients with a determination of BRAF status and presence of a mutation in the BRAF gen.&#xD;
FOLFOX/FOLFIRI + cetuximab 500mg/m2 bi-weekly for 6 months, then bi-weekly cetuximab as monotherapy.&#xD;
FOLFIRI (m): FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
FOLFOX-6 (m): FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
Cetuximab: - 500 mg/m2 i.v. Every 2 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="161"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="181"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="10.5"/>
                    <measurement group_id="B2" value="67" spread="7.4"/>
                    <measurement group_id="B3" value="65" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage</title>
          <description>The stage of a cancer describes the size and spread of a tumour:&#xD;
stage I - The cancer has grown through the mucosa and has invaded the muscular layer of the colon or rectum.&#xD;
stage II - The cancer has grown through the wall of the colon or rectum stage III - The cancer has grown through the inner lining or into the muscle layers of the intestine. It has spread to lymph nodes stage IV - The cancer has spread to a distant part of the body</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Stage I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stage II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stage III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stage IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary location</title>
          <description>Part of the colon where the primary tumor was located</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Ascending colon</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Transverse colon</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Descending colon</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Sigmoid colon</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rectum</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgery of the primary tumor</title>
          <description>Percentage of patients that had surgery for their primary colorectal tumor</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Performance Status (PS)</title>
          <description>Eastern Cooperative Oncology Group (ECOG) performance status. ECOG scale measures the performance status of a patients. It ranges from 0 (fully active, able to carry on all pre-disease performance without restriction) to 5 (death).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>ECOG 0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ECOG 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of metastatic organs</title>
          <description>Percentage of patients presenting metastasis in one or more distant organs. The number of patients with 1,2, 3 or more than 4 affected organs are reported</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 or higher</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival</title>
        <description>Measurements according to RECIST 1.1 criteria (Response Evaluation Criteria in Solid Tumors). Main techniques: CT-scan. Two groups will be defined based on the score built from the proposed clinical variables and biomarkers. Instead of a binomial distribution, a Log-rank method has been used to calculate the sample size in order to include all the incidents during the follow-up. Expecting a minimum 20% difference (60 vs. 40%) on PFS at 12 months between groups and with the following assumptions:&#xD;
Alpha error (bilateral): 5% Beta error: 20% Results are reported by subgroups to compare outcome measure according to BRAF mutation. All patients belong to same treatment/study arm.</description>
        <time_frame>4 years</time_frame>
        <population>Evaluable population</population>
        <group_list>
          <group group_id="O1">
            <title>WT BRAF - FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab</title>
            <description>Patients with a determination of BRAF status and presence of Wild type (WT) BRAF gen.&#xD;
FOLFOX/FOLFIRI + cetuximab 500mg/m2 bi-weekly for 6 months, then bi-weekly cetuximab as monotherapy.&#xD;
FOLFIRI (m): FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
FOLFOX-6 (m): FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
Cetuximab: - 500 mg/m2 i.v. Every 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mutant BRAF - FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab</title>
            <description>Patients with a determination of BRAF status and presence of a mutation in the BRAF gen.&#xD;
FOLFOX/FOLFIRI + cetuximab 500mg/m2 bi-weekly for 6 months, then bi-weekly cetuximab as monotherapy.&#xD;
FOLFIRI (m): FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
FOLFOX-6 (m): FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
Cetuximab: - 500 mg/m2 i.v. Every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Measurements according to RECIST 1.1 criteria (Response Evaluation Criteria in Solid Tumors). Main techniques: CT-scan. Two groups will be defined based on the score built from the proposed clinical variables and biomarkers. Instead of a binomial distribution, a Log-rank method has been used to calculate the sample size in order to include all the incidents during the follow-up. Expecting a minimum 20% difference (60 vs. 40%) on PFS at 12 months between groups and with the following assumptions:&#xD;
Alpha error (bilateral): 5% Beta error: 20% Results are reported by subgroups to compare outcome measure according to BRAF mutation. All patients belong to same treatment/study arm.</description>
          <population>Evaluable population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" lower_limit="9.9" upper_limit="13.1"/>
                    <measurement group_id="O2" value="5.9" lower_limit="3.3" upper_limit="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>3.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Measured as time in months from start of study treatment to death or lost to follow up.&#xD;
Results are reported by subgroups to compare outcome measure according to BRAF mutation. All patients belong to same treatment/study arm.</description>
        <time_frame>4 years</time_frame>
        <population>Evaluable population</population>
        <group_list>
          <group group_id="O1">
            <title>WT BRAF - FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab</title>
            <description>Patients with a determination of BRAF status and presence of Wild type (WT) BRAF gen.&#xD;
FOLFOX/FOLFIRI + cetuximab 500mg/m2 bi-weekly for 6 months, then bi-weekly cetuximab as monotherapy.&#xD;
FOLFIRI (m): FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
FOLFOX-6 (m): FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
Cetuximab: - 500 mg/m2 i.v. Every 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mutant BRAF - FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab</title>
            <description>Patients with a determination of BRAF status and presence of a mutation in the BRAF gen.&#xD;
FOLFOX/FOLFIRI + cetuximab 500mg/m2 bi-weekly for 6 months, then bi-weekly cetuximab as monotherapy.&#xD;
FOLFIRI (m): FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
FOLFOX-6 (m): FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
Cetuximab: - 500 mg/m2 i.v. Every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Measured as time in months from start of study treatment to death or lost to follow up.&#xD;
Results are reported by subgroups to compare outcome measure according to BRAF mutation. All patients belong to same treatment/study arm.</description>
          <population>Evaluable population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" lower_limit="27.5" upper_limit="38.8"/>
                    <measurement group_id="O2" value="9.3" lower_limit="5.3" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.33</ci_lower_limit>
            <ci_upper_limit>3.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Duration</title>
        <description>Duration of the partial or total response to the treatment. Evaluation and classification according to RECIST 1.1 criteria (Response Evaluation Criteria in Solid Tumors)</description>
        <time_frame>4 years</time_frame>
        <population>Evaluable population</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab</title>
            <description>FOLFOX/FOLFIRI + cetuximab 500mg/m2 bi-weekly for 6 months, then bi-weekly cetuximab as monotherapy.&#xD;
FOLFIRI (m): FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
FOLFOX-6 (m): FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
Cetuximab: - 500 mg/m2 i.v. Every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Duration</title>
          <description>Duration of the partial or total response to the treatment. Evaluation and classification according to RECIST 1.1 criteria (Response Evaluation Criteria in Solid Tumors)</description>
          <population>Evaluable population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.66" lower_limit="1.16" upper_limit="53.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Adverse Events</title>
        <description>Frequency and type of adverse events (AEs). AEs were coded according to NCI CTCAE V3.0 and classified by frequency, relatedness to study treatment (related/not related) and severity (Grade).&#xD;
Severity ranges from grade 1 (low intensity) to Grade 5 (max. intensity, death)</description>
        <time_frame>4 years</time_frame>
        <population>Safety population (all patients that received at least one infusion of study treatment)</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab</title>
            <description>FOLFOX/FOLFIRI + cetuximab 500mg/m2 bi-weekly for 6 months, then bi-weekly cetuximab as monotherapy.&#xD;
FOLFIRI (m): FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
FOLFOX-6 (m): FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
Cetuximab: - 500 mg/m2 i.v. Every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Adverse Events</title>
          <description>Frequency and type of adverse events (AEs). AEs were coded according to NCI CTCAE V3.0 and classified by frequency, relatedness to study treatment (related/not related) and severity (Grade).&#xD;
Severity ranges from grade 1 (low intensity) to Grade 5 (max. intensity, death)</description>
          <population>Safety population (all patients that received at least one infusion of study treatment)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <title>yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                  </measurement_list>
                </category>
                <category>
                  <title>no</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 or higher AEs</title>
              <category_list>
                <category>
                  <title>yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>no</title>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5 AEs</title>
              <category_list>
                <category>
                  <title>yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>no</title>
                  <measurement_list>
                    <measurement group_id="O1" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment related AEs of any grade</title>
              <category_list>
                <category>
                  <title>yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                  </measurement_list>
                </category>
                <category>
                  <title>no</title>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment related AEs grade 3 or higher</title>
              <category_list>
                <category>
                  <title>yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>no</title>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Biomarkers Analysis</title>
        <description>The secondary biomarkers in serum and tumoral tissue will be analysed in order to predict the acquired resistance.</description>
        <time_frame>4 years</time_frame>
        <population>Evaluable population</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab</title>
            <description>FOLFOX/FOLFIRI + cetuximab 500mg/m2 bi-weekly for 6 months, then bi-weekly cetuximab as monotherapy.&#xD;
FOLFIRI (m): FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
FOLFOX-6 (m): FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
Cetuximab: - 500 mg/m2 i.v. Every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Biomarkers Analysis</title>
          <description>The secondary biomarkers in serum and tumoral tissue will be analysed in order to predict the acquired resistance.</description>
          <population>Evaluable population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PI3K and PTEN</title>
              <category_list>
                <category>
                  <title>WT</title>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mutant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>UK</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGF-1RP/MMP7</title>
              <category_list>
                <category>
                  <title>WT</title>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mutant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>UK</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumoral Response</title>
        <description>Measurements according to RECIST 1.1 criteria (Response Evaluation Criteria in Solid Tumors). Main techniques: CT-scan. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR Results are reported by subgroups to compare outcome measure according to BRAF mutation. All patients belong to same treatment/study arm.</description>
        <time_frame>4 years</time_frame>
        <population>Evaluable population</population>
        <group_list>
          <group group_id="O1">
            <title>WT BRAF - FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab</title>
            <description>Patients with a determination of BRAF status and presence of Wild type (WT) BRAF gen.&#xD;
FOLFOX/FOLFIRI + cetuximab 500mg/m2 bi-weekly for 6 months, then bi-weekly cetuximab as monotherapy.&#xD;
FOLFIRI (m): FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
FOLFOX-6 (m): FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
Cetuximab: - 500 mg/m2 i.v. Every 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mutant BRAF - FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab</title>
            <description>Patients with a determination of BRAF status and presence of a mutation in the BRAF gen.&#xD;
FOLFOX/FOLFIRI + cetuximab 500mg/m2 bi-weekly for 6 months, then bi-weekly cetuximab as monotherapy.&#xD;
FOLFIRI (m): FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
FOLFOX-6 (m): FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
Cetuximab: - 500 mg/m2 i.v. Every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Tumoral Response</title>
          <description>Measurements according to RECIST 1.1 criteria (Response Evaluation Criteria in Solid Tumors). Main techniques: CT-scan. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR Results are reported by subgroups to compare outcome measure according to BRAF mutation. All patients belong to same treatment/study arm.</description>
          <population>Evaluable population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete response (CR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial response (PR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable disease (SD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progression disease (PD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not evaluable (NE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years</time_frame>
      <desc>Safety assessments included patient history and physical examinations, vital signs, ECOG PS, AEs, blood chemistry, and blood counts, which were performed at each visit.&#xD;
AE severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 3.0. Relation to cetuximab or chemotherapy (definitely, probably, possibly, unlikely, or unrelated) were assessed by the PI.&#xD;
AEs reported by treatment arm, which includes all patients</desc>
      <group_list>
        <group group_id="E1">
          <title>FOLFIRI (m) or FOLFOX-6 (m) + Cetuximab</title>
          <description>FOLFOX/FOLFIRI + cetuximab 500mg/m2 bi-weekly for 6 months, then bi-weekly cetuximab as monotherapy.&#xD;
FOLFIRI (m): FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
FOLFOX-6 (m): FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:&#xD;
Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.&#xD;
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.&#xD;
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.&#xD;
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.&#xD;
Cetuximab: - 500 mg/m2 i.v. Every 2 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Leucocytopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="53" subjects_affected="53" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular alterations non otherwise specified (NOS)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Ocular disorders NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>rectal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders NOS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hand-foot syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>General and site reactions NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic toxicity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Transaminitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Alergic reaction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Metabolic disorders NOS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscolosqueletal disorders NOS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>paresthesia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary disorders NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory disorders NOS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Skin reaction</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Xerosis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders NOS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="198" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>trichomegaly</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular disorders NOS</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="80" subjects_affected="80" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" events="47" subjects_affected="47" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="87" subjects_affected="87" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="60" subjects_affected="60" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Mucosa dryness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="101" subjects_affected="101" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pain NOS</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Transaminitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections NOS</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Metabolic disorders NOS</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal disorders NOS</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="72" subjects_affected="72" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="45" subjects_affected="45" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders NOS</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary disorders NOS</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory disorders NOS</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Cutaneous reaction</sub_title>
                <counts group_id="E1" events="134" subjects_affected="134" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Xerosis</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders NOS</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Complying with the R.D. 223/2004, the results of this trial will be published, both positive and negative results in recognized scientific journals or congress.&#xD;
The Sponsor and the Investigators are fully committed to publishing the results of the study.&#xD;
All publications (i.e., manuscripts, abstracts, oral / slide presentations, book chapters) based on this study must be submitted to the sponsor for review prior to publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joan Maurel Santasusana</name_or_title>
      <organization>GEMCAD</organization>
      <phone>+ 34 93 434 44 12</phone>
      <email>JMAUREL@clinic.cat</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

